HUTCHMED (China) Ltd
HCM13.550USD
+0.200+1.50%
終値 12/19, 16:00（ET）15分遅れの株価
11.82B時価総額
25.06直近12ヶ月PER
詳細情報 HUTCHMED (China) Ltd 企業名
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
HUTCHMED (China) Ltdの企業情報
企業コードHCM
会社名HUTCHMED (China) Ltd
上場日May 19, 2006
最高経営責任者「CEO」Cheng (Chig Fung)
従業員数1811
証券種類Depository Receipt
決算期末May 19
本社所在地48th Floor, Cheung Kong Center, 2 Queen's Road Central
都市
証券取引所NASDAQ OMX - NASDAQ BASIC
国Hong Kong
郵便番号- -
電話番号85221281188
ウェブサイトhttps://www.hutch-med.com/
企業コードHCM
上場日May 19, 2006
最高経営責任者「CEO」Cheng (Chig Fung)
HUTCHMED (China) Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
他の
97.71%
株主統計
株主統計
比率
Schroder Investment Management (Singapore) Ltd.
0.97%
Allianz Global Investors Asia Pacific Limited
0.49%
Schroder Investment Management (Hong Kong) Ltd.
0.45%
Jane Street Capital, L.L.C.
0.20%
State Street Investment Management (US)
0.18%
他の
97.71%
種類
株主統計
比率
Investment Advisor/Hedge Fund
2.31%
Investment Advisor
0.76%
Research Firm
0.22%
Hedge Fund
0.13%
Individual Investor
0.12%
Bank and Trust
0.03%
Sovereign Wealth Fund
0.01%
他の
96.41%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
144
6.22M
3.56%
-5.80M
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Schroder Investment Management (Singapore) Ltd.
1.77M
1.02%
-97.80K
-5.23%
Jun 30, 2025
Allianz Global Investors Asia Pacific Limited
878.74K
0.5%
-67.00K
-7.08%
Jun 30, 2025
Schroder Investment Management (Hong Kong) Ltd.
805.63K
0.46%
-166.36K
-17.12%
Jun 30, 2025
Jane Street Capital, L.L.C.
175.96K
0.1%
-46.28K
-20.82%
Jun 30, 2025
State Street Investment Management (US)
328.79K
0.19%
-8.07K
-2.40%
Jun 30, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Jun 30, 2025
Amundi Asset Management, SAS
157.43K
0.09%
--
--
Jun 30, 2025
M&G Investment Management Ltd.
259.62K
0.15%
+924.00
+0.36%
Jun 30, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
Renaissance Technologies LLC
129.00K
0.07%
-6.20K
-4.59%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Tema Oncology ETF
0.78%
National Security Emerging Markets Index ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
0%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Tema Oncology ETF
比率0.78%
National Security Emerging Markets Index ETF
比率0.35%
Invesco Nasdaq Biotechnology ETF
比率0.05%
ProShares Ultra Nasdaq Biotechnology
比率0.05%
DFA Dimensional Emerging Markets Core Equity 2 ETF
比率0%
DFA Dimensional Em Mkts Sustainability Core 1 ETF
比率0%
ActivePassive International Equity ETF
比率0%
SPDR Portfolio Developed World ex-US ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
よくある質問
HUTCHMED (China) Ltdの上位5名の株主は誰ですか？
HUTCHMED (China) Ltdの上位5名の株主は以下のとおりです。
Schroder Investment Management (Singapore) Ltd.は1.77M株を保有しており、これは全体の1.02%に相当します。
Allianz Global Investors Asia Pacific Limitedは878.74K株を保有しており、これは全体の0.50%に相当します。
Schroder Investment Management (Hong Kong) Ltd.は805.63K株を保有しており、これは全体の0.46%に相当します。
Jane Street Capital, L.L.C.は175.96K株を保有しており、これは全体の0.10%に相当します。
State Street Investment Management (US)は328.79K株を保有しており、これは全体の0.19%に相当します。
Schroder Investment Management (Singapore) Ltd.は1.77M株を保有しており、これは全体の1.02%に相当します。
Allianz Global Investors Asia Pacific Limitedは878.74K株を保有しており、これは全体の0.50%に相当します。
Schroder Investment Management (Hong Kong) Ltd.は805.63K株を保有しており、これは全体の0.46%に相当します。
Jane Street Capital, L.L.C.は175.96K株を保有しており、これは全体の0.10%に相当します。
State Street Investment Management (US)は328.79K株を保有しており、これは全体の0.19%に相当します。
HUTCHMED (China) Ltdの株主タイプ上位3種は何ですか？
HUTCHMED (China) Ltdの株主タイプ上位3種は、
Schroder Investment Management (Singapore) Ltd.
Allianz Global Investors Asia Pacific Limited
Schroder Investment Management (Hong Kong) Ltd.
Schroder Investment Management (Singapore) Ltd.
Allianz Global Investors Asia Pacific Limited
Schroder Investment Management (Hong Kong) Ltd.
HUTCHMED (China) Ltd（HCM）の株式を保有している機関の数はいくつですか？
2025Q3時点で、HUTCHMED (China) Ltdの株式を保有している機関は144社あり、保有株式の総市場価値は約6.22Mで、全体の3.56%を占めています。2025Q2と比較して、機関の持ち株は-0.43%増加しています。
HUTCHMED (China) Ltdの最大の収益源は何ですか？
FY2024において、--部門がHUTCHMED (China) Ltdにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
